Synthetic Virus-Like Particles (sVLP™)

An ability of NanoElectroPlex™ to package proteins is being used to address limitations in the revolutionary Virus-Like Particle (VLP) technology making major advances for vaccines.  NanoElectroPlex™ has been adapted to display whole antigens, or small peptide epitopes, with designer adjuvants, on nanoparticle surface, generating structures resembling viral particles for delivery to cells in the immune system, synthetic VLP (sVLP™).  The sVLP™ are far simpler to develop and produce, but far more versatile in incorporating different types of antigens and adjuvants within the same structure. They bring together functional components not possible with VLP.

AparnaBio received NIH funding to use NanoElectroPlexTM to co-package two anthrax antigens, one of which is by itself poorly immunogenic.  The studies achieved an sVLP™ with an unusually short timeframe that could elicit an unprecedented immune response to both antigens, a dual antigen vaccine.  The simple process of developing and assembling the NanoElectroPlex™ based sVLP™ vaccine is depicted below.  This first generation sVLP™ has demonstrated a capability to induce an immune response to even very weak antigens.  With simplicity and powerful effectiveness of tissue targeting, the sVLP™ technology is readily adapted for rapid development of a broad range of prophylactic vaccines.